Thera Liechtenstein is a manager at Industrie- und Finanzkontor in Vaduz, Liechtenstein.
She previously worked as a biologist in the field of cancer research and immunology and worked at University College London, UK, and at Navarrabiomed Fundación Miguel Servet, in Pamplona, Spain, for her Phd graduate studies.
Her work led to the development of an ex vivo myeloid-derived suppressor cell production system, which was patented in Europe. She also published several biomedical papers in the field of cancer immunotherapy.
Before her PhD studies she worked on pancreatic cancer cell biology and resistance to chemotherapeutic drugs at the Centre for Experimental Molecular Medicine, Academic Medical Centre in Amsterdam, Netherlands. She also worked on the patentability of human peptides as potential candidates for the treatment of orphan diseases at mondoBIOTECH, Stans, Switzerland.
Thera Liechtenstein has a BA degree in biology and business studies from New York University and a MSc degree in biomedical sciences from the University of Amsterdam.